Immutep Reports Initial Safety Data For IMP761, The First LAG-3 Agonist, In Phase I Trial With No Treatment-Related Adverse Events; Additional Data Expected In H1 2025 To Support Autoimmune Disease Treatment Potential
Immutep Reports Initial Safety Data For IMP761, The First LAG-3 Agonist, In Phase I Trial With No Treatment-Related Adverse Events; Additional Data Expected In H1 2025 To Support Autoimmune Disease Treatment Potential
Immutep報告IMP761的初步安全數據，這是首個LAG-3激動劑，在I期臨床試驗中未出現治療相關的不良事件；預計在2025年上半年將發佈額外數據以支持自身免疫疾病的治療潛力。
Immutep Reports Initial Safety Data For IMP761, The First LAG-3 Agonist, In Phase I Trial With No Treatment-Related Adverse Events; Additional Data Expected In H1 2025 To Support Autoimmune Disease Treatment Potential
Immutep報告IMP761的初步安全數據，這是首個LAG-3激動劑，在I期臨牀試驗中未出現治療相關的不良事件；預計在2025年上半年將發佈額外數據以支持自身免疫疾病的治療潛力。
資訊熱榜
更新時間